Paper3940216
CB 1954 revisited. I. Disposition kinetics and metabolism.
Workman P and 2 others. Cancer Chemother Pharmacol, 1986. Cited by 31 papers, by iCite.
Cite this record
ConductScience Library. CB 1954 revisited. I. Disposition kinetics and metabolism. Papers, record 3940216. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3940216
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Aziridines | Major topic |
| Azirines | Major topic |
| Allopurinol | |
| Animals | |
| Biotransformation | |
| Brain | |
| Dogs | |
| Drug Interactions | |
| Kinetics | |
| Male | |
| Metabolic Clearance Rate | |
| Mice | |
| Mice, Inbred Strains | |
| Neoplasms, Experimental | |
| Phenobarbital |
Source PubMed
References28
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 7273265 | Structure-pharmacokinetic relationships for misonidazole analogues in mice. | Cancer Chemother Pharmacol | 1981 | https://conductscience.org/library/papers/7273265 | PubMed |
| 2 | 1170190 | Medicinal nitro-compounds. Part II. Search for ortho-interactions in tumour-inhibitory 2,4-dinitrophenylaziridines. | J Chem Soc Perkin 1 | 1975 | https://conductscience.org/library/papers/1170190 | PubMed |
| 3 | 5404002 | A spectrophotometric method for the estimation of the carcinostatic agent, 5-aziridino-2,4-dinitrobenzamide (CB 1954), in biological fluids. | Biochem Pharmacol | 1969 | https://conductscience.org/library/papers/5404002 | PubMed |
| 4 | 7313077 | Radiosensitizing and cytotoxicity studies with CB 1954 (2,4-dinitro-5-aziridinylbenzamide). | Radiat Res | 1981 | https://conductscience.org/library/papers/7313077 | PubMed |
| 5 | 985569 | The metabolism of the anti-tumour agent 5-(1-aziridinyl)-2,4-dinitrobenzamide (CB 1954). | Biochem Pharmacol | 1976 | https://conductscience.org/library/papers/985569 | PubMed |
| 6 | 528273 | The effect of time between X-irradiation and chemotherapy on the growth of three solid mouse tumors--I. Adriamycin. | Int J Radiat Oncol Biol Phys | 1979 | https://conductscience.org/library/papers/528273 | PubMed |
| 7 | 7002161 | Selective inhibition of ribonucleotide reductase by the monofunctional alkylating agent 5(1-aziridinyl)-2,4-dinitrobenzamide (CB 1954). | Biochem Pharmacol | 1980 | https://conductscience.org/library/papers/7002161 | PubMed |
| 8 | 6547051 | Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo. | Br J Cancer | 1984 | https://conductscience.org/library/papers/6547051 | PubMed |
| 9 | 6932916 | The response of a human tumour xenograft to chemotherapy: intrinsic variation between tumours and its significance in planning experiments. | Br J Cancer Suppl | 1980 | https://conductscience.org/library/papers/6932916 | PubMed |
| 10 | 5156332 | Tumour-growth inhibitory nitrophenylaziridines and related compounds: structure-activity relationships. II. | Chem Biol Interact | 1971 | https://conductscience.org/library/papers/5156332 | PubMed |
| 11 | 4307990 | 2,4-dinitro-5-ethyleneiminobenzamide (CB 1954): a potent and selective inhibitor of the growth of the Walker carcinoma 256. | Biochem Pharmacol | 1969 | https://conductscience.org/library/papers/4307990 | PubMed |
| 12 | 5407053 | Tumour-growth inhibitory nitrophenylaziridines and related compounds: structure-activity relationships. | Chem Biol Interact | 1969 | https://conductscience.org/library/papers/5407053 | PubMed |
| 13 | 7370166 | Pharmacokinetic and tumour-penetration properties of the hypoxic cell radiosensitizer desmethylmisonidazole (Ro 05-Ro-9963) in dogs. | Br J Cancer | 1980 | https://conductscience.org/library/papers/7370166 | PubMed |
| 14 | 6466543 | Preclinical pharmacokinetics of benznidazole. | Br J Cancer | 1984 | https://conductscience.org/library/papers/6466543 | PubMed |
| 15 | 4855748 | Studies on the mechanism of action of 5-aziridinyl-2, 4-dinitrobenzamide in tumor cells. | Cancer Res | 1974 | https://conductscience.org/library/papers/4855748 | PubMed |
| 16 | 3940225 | CB 1954 revisited. II. Toxicity and antitumour activity. | Cancer Chemother Pharmacol | 1986 | https://conductscience.org/library/papers/3940225 | PubMed |
| 17 | 940937 | Electron-affinic sensitization. VII. A correlation between structures, one-electron reduction potentials, and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers. | Radiat Res | 1976 | https://conductscience.org/library/papers/940937 | PubMed |
| 18 | 7460192 | Dose-dependence and related studies on the pharmacokinetics of misonidazole and desmethylmisonidazole in mice. | Cancer Chemother Pharmacol | 1980 | https://conductscience.org/library/papers/7460192 | PubMed |
| 19 | 659541 | Estimation of the hypoxic cell-sensitiser misonidazole and its O-demethylated metabolite in biological materials by reversed-phase high-performance liquid chromatography. | J Chromatogr | 1978 | https://conductscience.org/library/papers/659541 | PubMed |
| 20 | 36083 | Metabolic activation of nitrofurantoin--possible implications for carcinogenesis. | Biochem Pharmacol | 1979 | https://conductscience.org/library/papers/36083 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 31 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 19924084 | Bystander or no bystander for gene directed enzyme prodrug therapy. | Molecules | 2009 | https://conductscience.org/library/papers/19924084 | PubMed |
| 17768344 | Crystallization and preliminary X-ray characterization of the Bacillus amyloliquefaciens YwrO enzyme. | Acta Crystallogr Sect F Struct Biol Cryst Commun | 2007 | https://conductscience.org/library/papers/17768344 | PubMed |
| 12888809 | Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK. | Br J Cancer | 2003 | https://conductscience.org/library/papers/12888809 | PubMed |
| 8375021 | The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT). | Cancer Metastasis Rev | 1993 | https://conductscience.org/library/papers/8375021 | PubMed |
| 3940225 | CB 1954 revisited. II. Toxicity and antitumour activity. | Cancer Chemother Pharmacol | 1986 | https://conductscience.org/library/papers/3940225 | PubMed |
| 3168141 | Pharmacokinetics and metabolism of the mixed-function hypoxic cell sensitizer prototype RSU 1069 in mice. | Cancer Chemother Pharmacol | 1988 | https://conductscience.org/library/papers/3168141 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/3940216
GET https://conductscience.org/api/papers/v1/3940216/references?page=2